InxMed Says FAK Inhibitor Effective Against Resistance to KRAS Inhibitors
June 25, 2021 at 05:23 AM EDT
InxMed ( Shanghai ) reported that its FAK inhibitor (IN10018) was effective in preventing resistance to KRAS G12C inhibitors in preclinical tests. The study showed that KRAS G12C inhibitors activate focal adhesive kinase (FAK), causing drug resistance. A combination of InxMed's IN10018 and a KRAS G12C inhibitor was effective in several different preclinical models. The study was completed in collaboration with Ruijin Hospital , Shanghai Jiaotong University School of Medicine and published in an online publication, Advanced Science. More details.... Share this with colleagues: // //
